175 related articles for article (PubMed ID: 35848061)
21. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
Fishman MN; Srinivas S; Hauke RJ; Amato RJ; Esteves B; Cotreau MM; Strahs AL; Slichenmyer WJ; Bhargava P; Kabbinavar FF
Eur J Cancer; 2013 Sep; 49(13):2841-50. PubMed ID: 23726267
[TBL] [Abstract][Full Text] [Related]
22. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Meza L; McDermott DF; Escudier B; Hutson TE; Porta C; Verzoni E; Atkins MB; Kasturi V; Pal SK; Rini B
Oncologist; 2023 Mar; 28(3):e167-e170. PubMed ID: 36576430
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors.
Niwakawa M; Yamaguchi R; Onozawa Y; Yasui H; Taku K; Naito T; Akinaga S; Boku N; Yamamoto N
Cancer Sci; 2013 Aug; 104(8):1039-44. PubMed ID: 23679664
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
Molina AM; Hutson TE; Nosov D; Tomczak P; Lipatov O; Sternberg CN; Motzer R; Eisen T
Eur J Cancer; 2018 May; 94():87-94. PubMed ID: 29547835
[TBL] [Abstract][Full Text] [Related]
25. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
Zahoor H; Rini BI
Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664
[TBL] [Abstract][Full Text] [Related]
26. Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; Powers D; McDermott DF; Rini BI
Eur Urol; 2020 Dec; 78(6):783-785. PubMed ID: 32938569
[TBL] [Abstract][Full Text] [Related]
27. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus.
Vázquez Estévez S; Anido U; Lázaro M; Fernández O; Fernández Núñez N; de Dios Álvarez N; Varela V; Campos Balea B; Agraso S; Areses MC; Iglesias L; Blanco M; Maciá S; Anton Aparicio LM
Clin Transl Oncol; 2020 Sep; 22(9):1565-1579. PubMed ID: 32062835
[TBL] [Abstract][Full Text] [Related]
28. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
29. Tivozanib: current status and future directions in the treatment of solid tumors.
Pal SK; Bergerot PG; Figlin RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1851-9. PubMed ID: 23013465
[TBL] [Abstract][Full Text] [Related]
30. Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma.
Sakellakis M; Zakopoulou R
Cureus; 2023 Mar; 15(3):e35675. PubMed ID: 37012938
[TBL] [Abstract][Full Text] [Related]
31. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors.
De Luca A; Normanno N
IDrugs; 2010 Sep; 13(9):636-45. PubMed ID: 20799147
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
Kalpathy-Cramer J; Chandra V; Da X; Ou Y; Emblem KE; Muzikansky A; Cai X; Douw L; Evans JG; Dietrich J; Chi AS; Wen PY; Stufflebeam S; Rosen B; Duda DG; Jain RK; Batchelor TT; Gerstner ER
J Neurooncol; 2017 Feb; 131(3):603-610. PubMed ID: 27853960
[TBL] [Abstract][Full Text] [Related]
33. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Fogli S; Porta C; Del Re M; Crucitta S; Gianfilippo G; Danesi R; Rini BI; Schmidinger M
Cancer Treat Rev; 2020 Mar; 84():101966. PubMed ID: 32044644
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
35. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
[TBL] [Abstract][Full Text] [Related]
36. Tivozanib: status of development.
Jamil MO; Hathaway A; Mehta A
Curr Oncol Rep; 2015 Jun; 17(6):24. PubMed ID: 25895472
[TBL] [Abstract][Full Text] [Related]
37. Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma.
Yalcin S; Lacin S
Cancer Manag Res; 2019; 11():7779-7785. PubMed ID: 31496820
[TBL] [Abstract][Full Text] [Related]
38. Lenvatinib for the treatment of kidney cancer.
Študentová H; Vitásková D; Melichar B
Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
[TBL] [Abstract][Full Text] [Related]
40. Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).
Haberkorn BC; Eskens FA
Future Oncol; 2013 Jan; 9(1):13-20. PubMed ID: 23252559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
